BioCentury | Apr 18, 2020
Finance

April 17 Quick Takes: Mabworks’ $160M series C; plus RDMD, PIC, SIRS, Atomo and Lantern

Beijing antibody play Mabworks raises $160M  Mabworks Biotech Co. Ltd. raised RMB1.1 billion ($160 million) in series C1 and C2 rounds to support development and commercialization of its antibody pipeline for various cancers, autoimmune, metabolic...
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an additional RMB470 million in a series C2 round to advance its RNAi and antisense...
BC Extra | Apr 29, 2019
Financial News

April 29 Quick Takes: Sirnaomics, Codiak, Cortexyme, Milestone, NextCure, Applied Therapeutics, Magenta

Sirnaomics closes $47M series C  RNAi therapeutics company Sirnaomics Inc. (Gaithersburg, Md.) raised $22 million in a series C2 round led by Hong Kong-based CR-CP Life Sciences Fund, closing out its series C round for...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Innovations | Jun 29, 2017
Translation in Brief

Tilt a flavin

A team from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the University of Edinburgh has solved a problem that has stymied the development of kynurenine 3-monoxygenase (KMO) inhibitors -- the production of cytotoxic hydrogen peroxide -- and...
BC Week In Review | Jun 22, 2015
Clinical News

Arzerra ofatumumab: Additional Phase III data

Additional data from the open-label, international Phase III COMPLEMENT 2 trial in 365 patients with relapsed CLL showed that IV Arzerra plus fludarabine and cyclophosphamide led to a median PFS, the primary endpoint, of 28.9...
BC Week In Review | May 4, 2015
Clinical News

Arzerra ofatumumab: Phase III data

Top-line data from the open-label, international Phase III COMPLEMENT 2 trial in 365 patients with relapsed CLL showed that IV Arzerra plus fludarabine and cyclophosphamide met the primary endpoint of improving PFS vs. fludarabine and...
BioCentury | Dec 15, 2014
Strategy

Momenta moving on

Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc. 's novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics....
BC Week In Review | Nov 25, 2013
Clinical News

Lampalizumab: Additional Phase II data

Roche's Genentech Inc. unit disclosed the details of an exploratory biomarker from the single-blind Phase II MAHALO trial evaluating lampalizumab to treat GA associated with AMD. In August, data from 129 patients in MAHALO showed...
BC Extra | Nov 19, 2013
Clinical News

Genentech details biomarkers for lampalizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) disclosed the details of an exploratory biomarker for the company's lampalizumab ( RG7417 ), which is in development to treat geographic atrophy (GA), an advanced form of dry...
Items per page:
1 - 10 of 60